N/A
N=20
Empowering LGBTQ+ Tobacco Cessation Pilot
Smoking Cessation
Bottom Line
View on ClinicalTrials.gov: NCT05365633 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Retention — 16 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Empowerment activity-enhanced tobacco cessation assistance (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Oklahoma
- Primary completion
- Sep 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Retention |
16 | — |
| PRIMARY Number of Participants Endorsing That They Would Recommend This Intervention to Another LGBTQ2S+ Identified Person Who Wants to Quit Smoking |
13 | — |
| PRIMARY Number of Community Partner Staff Who Perceived Their Organization's Partnership on the Intervention as Beneficial |
2 | — |
| PRIMARY Number of Participants Having Had ≥ 2 Weeks With Moderate to High Adherence to the Nicotine Patch Assessed With the 4-item Medication Adherence Questionnaire (MAQ) |
11 | — |
| PRIMARY Number of Participants Attending at Least 4 Smoking Cessation Counseling Sessions |
14 | — |
| PRIMARY Number of Participants Attending at Least 4 Volunteer Sessions |
10 | — |
| SECONDARY Number of Participants Self-reporting 7-day Point Prevalence Abstinence at Week 12 |
9 | — |
| SECONDARY Number of Participants for Whom Self-reported Smoking Abstinence is Biochemically-verified |
4 | — |
| SECONDARY Number of Participants Who Reported an Increase in Adaptive Coping From Baseline to Exit |
1 | — |
Summary
Sexual and/or gender minority (SGM) people have disproportionately high rates of tobacco use - the number one cause of preventable death. Reasons for this include using tobacco to cope with social minority stressors, pro-tobacco use norms in SGM social spaces and networks, and targeted tobacco industry marketing. Empowerment Theory explains how positive behavior change, like quitting smoking, can be promoted through skills development with greater participation in the public affairs of one's community. An empowerment approach may enhance tobacco cessation treatment for SGM people and other stigmatized groups because it links individual well-being with the larger social and political context. This pilot study will assess the acceptability, feasibility, and preliminary impact of empowerment-enhanced tobacco smoking cessation assistance for SGM adults. We will enroll N=20 SGM adults in Oklahoma who smoke and are willing to quit. Participants will receive standard tobacco cessation assistance through the Stephenson Cancer Center Tobacco Treatment Research Program (TTRP). Concurrently, they will also engage in 'empowerment activities', meaning SGM organizing and community-building activities, like conducting follow-up phone calls to name change clinic participants. This will be guided by an Oklahoman SGM-serving community partner. Participants will complete 8 surveys during the intervention period and 12 weeks post-quit-date, a 60-minute, in-depth exit interview, and biochemically-verified smoking status before the intervention and 12 weeks post-quit-date. This pilot study will establish collaborative relationships between the PI's team and local SGM-serving organizations, and will produce preliminary findings to support future R01-level funding to conduct a fully-powered randomized control trial of a multi-level empowerment-enhanced SGM tobacco cessation intervention.
Eligibility Criteria
Inclusion Criteria
- At least 18 years old
- Self-identify as sexual and/or gender minority
- Reside in the State of Oklahoma
- Report past 30 day use of combustible tobacco
- Willing to quit using combustible tobacco within the next 2 weeks
- English-speaking
- Willing to refrain from smoking any substance, such as cannabis, within 48 hours of expired carbon monoxide collection
- Willing to complete all intervention components and data collection activities
Exclusion Criteria
- Have contraindications for nicotine replacement therapy (NRT)
Data sourced from ClinicalTrials.gov (NCT05365633). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.